Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature
- 1 January 2015
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (1) , 62-74
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- A Review of Pharmaceutical Agents and Oral Bone Health: How Osteonecrosis of the Jaw Has Affected the FieldThe International Journal of Oral and Maxillofacial Implants, 2014
- Bisphosphonate-related osteonecrosis of the jaws – Characteristics, risk factors, clinical features, localization and impact on oncological treatmentJournal of Cranio-Maxillofacial Surgery, 2012
- Bisphosphonates: The first 40yearsBone, 2011
- Osteonecrosis of the jaws induced by anti-RANK ligand therapyBritish Journal of Oral and Maxillofacial Surgery, 2010
- American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate‐Related Osteonecrosis of the Jaw – 2009 UpdateAustralian Endodontic Journal, 2009
- 2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 studyEuropean Journal of Cancer Supplements, 2009
- Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2007
- American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the JawsJournal of Oral and Maxillofacial Surgery, 2007
- Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatmentThe Lancet Oncology, 2006
- Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJournal of Oral and Maxillofacial Surgery, 2003